Clinical Trials Logo
  1. Home
  2. Primary Sclerosing Cholangitis
  3. NCT06095986

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis Clinical Trial

Official title:
A Proof of Concept, Prospective, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients With Primary Sclerosing Cholangitis

Clinical Trial Summary

The objectives of this study is to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients with Primary Sclerosing Cholangitis

Clinical Trial Description

The objectives of this study are to: - Establish the safety and tolerability of once daily (QD) Aramchol meglumine in patients with PSC - Examine whether once daily (QD) Aramchol meglumine has any effect on serum alkaline phosphatase - Provide a comprehensive readout of clinical efficacy following once daily (QD) Aramchol meglumine administration ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06095986
Study type Interventional
Source Galmed Pharmaceuticals Ltd
Contact Yossi Gilgun-Sherki, PhD, MBA
Phone +972543314054
Email yossigs@galmedpharma.com
Status Not yet recruiting
Phase Phase 2
Start date June 2024
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis Phase 2
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Completed NCT04024813 - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Phase 2
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A